Veru Receives Patent Allowance for Enobosarm with Weight Loss Drugs
Veru Inc. announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering compositions of selective androgen receptor modulator compounds, including enobosarm, in combination with weight loss drugs. This patent, when issued, will provide protection until at least October 2044 and strengthens the company's intellectual property portfolio for enobosarm in quality weight loss. The allowed claims encompass various treatment regimens and benefits, such as preserving lean body mass, enhancing fat loss, and preventing weight rebound after discontinuing GLP-1 RA therapy. The company also highlighted its ongoing Phase 2b PLATEAU study and positive results from the completed Phase 2b QUALITY study.
Key Highlights
- USPTO issued a Notice of Allowance for a U.S. patent application for enobosarm in combination with weight loss drugs.
- The patent, when issued, will provide protection until at least October 3, 2044.
- Allowed claims cover treatment regimens using enobosarm concurrently with semaglutide, or as monotherapy after semaglutide discontinuation.
- Claims are directed to preserving lean body mass, enhancing fat mass loss, improving physical function, and preventing weight rebound.
- The Phase 2b PLATEAU clinical study is fully enrolled, with interim results expected in Q1 2027 and final data in Q4 2027.
- The completed Phase 2b QUALITY clinical study demonstrated positive results for enobosarm in preserving lean mass and preventing fat/weight rebound.
Price Impact
More from VERU